Letter to the Editor
Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysisAuthor links open overlay panel,
,
,
,
,
,
,
,
,
,
,
Highlights
- •
Severe and critical COVID-19 patients experience high frequency of bacteremia.
- •
Bacteremia might be more frequent in remdesivir treated patients.
- •
Gram positive bacteria, especially Enterococcus faecalis are of special concern.
- •
Occurrence of bacteremia moderates association of remdesivir use with survival.
Keywords
SARS-CoV-2
Blood cultures
Immunosuppression
Bacteremia
View Abstract© 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.